AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32186238
Drug: Suction suspension
RxNorm normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suction suspension
Trial: 34193262
Drug: Combined Lactobacillus
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Lactobacillus reuteri and ω‐3 fatty acid treatment (double-treatment)
Trial: 34193262
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri (single treatment)
Trial: 34193262
Drug: ω‐3 fatty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐3 fatty acid (single treatment)
Trial: 35704085
Drug: B‐vitamin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B‐vitamin supplementation (400 µg folic acid and 500 µg vitamin B12 daily for 2 years)
Trial: 33900319
Drug: Modified alcohol-free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified alcohol-free beer (16.5 g isomaltulose and 5.28 g resistant maltodextrin per day)
Trial: 33390191
Drug: Digital intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital intervention to increase adherence to nebuliser treatments, details on dosage and duration not specified.
Trial: 32037213
Drug: Oral fluid
RxNorm normalized name: cascara sagrada ORAL FLUID EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fluid management group (OFG)
Trial: 35615299
Drug: Short course
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short course antibiotics (7 days)
Trial: 35615299
Drug: Conventional course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional course antibiotics (14 days)
Trial: 33721922
Drug: Low-cost and
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-cost and culturally acceptable treatment focusing on quality-of-life issues.
Trial: 33721922
Drug: Integrative model
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrative model of treatment incorporating traditional practices and community support.
Trial: 35027013
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (AFO/adapted shoes) for 12 weeks
Trial: 33764803
Drug: Angiotensin Converting
RxNorm normalized name: Angiotensin converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin Converting Enzyme (ACE) inhibitors
Trial: 33764803
Drug: Angiotensin‐2 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin‐2 receptor blockers (ARBs)
Trial: 32500675
Drug: PCSA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCSA with morphine
Trial: 32404130
Drug: Daily one-way
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily one-way text message intervention for 6 months
Trial: 34119811
Drug: Hypnosis (used
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypnosis (used in one or several sessions, alone or as an adjunct, reinforced with daily self-hypnosis with or without audio tapes)
Trial: 35605188
Drug: Lorlatinib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib (100 mg once daily)
Trial: 35605188
Drug: Crizotinib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crizotinib (250 mg twice a day)
Trial: 33098995
Drug: Paclitaxel (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (80 mg/m2 weekly) plus Olaparib (100 mg twice daily for 12 weeks)
Trial: 33098995
Drug: Paclitaxel plus
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel plus Carboplatinum (AUC 2 weekly for 12 weeks)
Trial: 33855585
Drug: Baseline IL-6
RxNorm normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline IL-6 cut-off value of 8.58 pg/mL
Trial: 33855585
Drug: Baseline IL-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline IL-8 cut-off value of 57.9 pg/mL
Trial: 33408308
Drug: Docetaxel/Nedaplatin (60/80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel/Nedaplatin (60/80 mg/m2/day)
Trial: 33408308
Drug: Docetaxel (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (70 mg/m2/day)
Trial: 32621073
Drug: Cabergoline (dopamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline (dopamine D2 agonist)
Trial: 32692751
Drug: Protein-calorie food
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein-calorie food supplement offered daily to pregnant and lactating women (2.09 MJ energy and 20-25 g protein) and their offspring (1.25 MJ energy and 8-10 g protein) until the age of six years.
Trial: 34265255
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection then progressive exercise
Trial: 34265255
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection then best practice advice
Trial: 32268257
Drug: Augmented biofeedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmented biofeedback training alongside traditional physical therapy
Trial: 32268257
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of augmented biofeedback training and traditional physical therapy
Trial: 34485754
Drug: Calcium chloride
RxNorm normalized name: Calcium Chloride
DrugBank: Calcium chloride (DB01164)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium chloride (15 mg/kg) administered intravenously as a bolus at the beginning of weaning from CPB
Trial: 34485754
Drug: 0.9% sodium
RxNorm normalized name: LMD with 0.9% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride administered intravenously as a bolus at the beginning of weaning from CPB
Trial: 33616190
Drug: treatment-as-usual control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment-as-usual control group
Trial: 34479732
Drug: Contrast agent
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast agent applied to the posterior ulnar recurrent artery
Trial: 34479732
Drug: Contrast agent
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast agent applied to the inferior ulnar collateral artery
Trial: 34479732
Drug: Contrast agent
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast agent applied to the superior ulnar collateral artery
Trial: 35863991
Drug: Bevacizumab (BEV)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab (BEV) during second-line chemotherapy
Trial: 35863991
Drug: Non-Bevacizumab (non-BEV)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Non-Bevacizumab (non-BEV) during second-line chemotherapy
Trial: 33472921
Drug: IV tPA
RxNorm normalized name: tPA
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV tPA treatment
Trial: 37697134
Drug: Sildenafil (PDE-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (PDE-5 inhibitor)
Trial: 35556322
Drug: Beetroot juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot juice (BRJ; 140 ml containing 800 mg nitrate per day)
Trial: 35556322
Drug: Placebo (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (140 ml nitrate-depleted BRJ, daily)
Trial: 32093630
Drug: Treatment 1
RxNorm normalized name: CVS Acne Treatment 10% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 1 (T1) - messages with information on their own adherence levels
Trial: 32093630
Drug: Treatment 2
RxNorm normalized name: epoch Blemish Treatment 2 % Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 2 (T2) - messages with information on their own adherence and peer adherence levels
Trial: 35709207
Drug: Face-to-face (FTF)
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face (FTF) pain management education in seven weekly sessions
Trial: 32139267
Drug: Eldecalcitol (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eldecalcitol (0.75 μg/day)
Trial: 33396567
Drug: Long chain
RxNorm normalized name: long chain triglycerides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long chain omega-3 polyunsaturated fatty acids (LC n-3 PUFAs) at a dosage of 1.8 g/day for 12 weeks
Trial: 36867173
Drug: Bupropion augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion augmentation
Trial: 33117349
Drug: High throughput
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High throughput screening platform using one-bead-one-compound (OBOC) libraries for IgE epitope detection.
Trial: 35995130
Drug: School-supervised asthma
RxNorm normalized name: schorl tourmaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-supervised asthma therapy
Trial: 34171959
Drug: Vericiguat (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vericiguat (target dose 10 mg once daily)
Trial: 34999610
Drug: Ulinastatin (300,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulinastatin (300,000 units mixed with 100 mL of normal saline)
Trial: 34999610
Drug: Control (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (100 mL of normal saline)
Trial: 33634589
Drug: liraglutide (0.6,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liraglutide (0.6, 1.2, and 1.8 mg/day)
Trial: 32791720
Drug: Ear molding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ear molding treatment for 2 weeks within 3 days after birth
Trial: 36512912
Drug: Durvalumab 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab 1500 mg (Arm 1)
Trial: 36512912
Drug: Durvalumab 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab 1500 mg plus tremelimumab 75 mg every 4 weeks (Arm 2)
Trial: 32619648
Drug: Omission of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omission of week 5 chemotherapy
Trial: 32619648
Drug: Dose reductions/delays
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose reductions/delays of week 5 chemotherapy
Trial: 32619648
Drug: Receiving the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receiving the target radiotherapy dose in >42 days
Trial: 36441436
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg daily)
Trial: 32072743
Drug: HIV combination
RxNorm normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV combination prevention package including universal testing and treatment
Trial: 35368954
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (single drug group)
Trial: 33227569
Drug: Pyridoxine treatment
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyridoxine treatment
Trial: 33004239
Drug: DAR-901 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAR-901 vaccine (1 mg, three intradermal injections at 0, 2, and 4 months)
Trial: 33004239
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo (three intradermal injections at 0, 2, and 4 months)
Trial: 33004239
Drug: DAR-901 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAR-901 vaccine (1 mg)
Trial: 35750727
Drug: Traditional implant
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional implant guide (traditional impression)
Trial: 33759846
Drug: Online interactive
RxNorm normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online interactive case-based training on evidence-based practice (EBP) related to medication use in autism
Trial: 35060851
Drug: Prednisolone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (15 mg/m2 for 6 days)
Trial: 35285944
Drug: Oral low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral low-dose isotretinoin (0.2–0.4 mg/kg/d) combined with 30% salicylic acid chemical peeling
Trial: 35285944
Drug: Oral low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral low-dose isotretinoin
Trial: 32692788
Drug: Topical budesonide
RxNorm normalized name: budesonide Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical budesonide irrigations
Trial: 32687588
Drug: Reduced-dose capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Reduced-dose capecitabine plus cetuximab as maintenance therapy
Trial: 32687588
Drug: Fluorouracil-based chemotherapy
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil-based chemotherapy combined with cetuximab (induction therapy)
Trial: 34008442
Drug: Insulin pen
RxNorm normalized name: INSULIN PEN (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin pen
Trial: 36348150
Drug: LED therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LED therapy (LEDT)
Trial: 34579095
Drug: RES-500 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RES-500 (500 mg RES/day)
Trial: 34579095
Drug: RES-1000 (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RES-1000 (1000 mg RES/day)
Trial: 34579095
Drug: RES (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RES (both doses)
Trial: 35048107
Drug: Polypill (aspirin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypill (aspirin, atorvastatin, hydrochlorothiazide, valsartan)
Trial: 35048107
Drug: Polypill (aspirin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypill (aspirin, atorvastatin, hydrochlorothiazide, valsartan) in participants with pNASH
Trial: 32340074
Drug: Biological with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological with Prevention (B + P)
Trial: 32340074
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment arms (C + P, B + P, PA)
Trial: 32963103
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (72 IU)
Trial: 32963103
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (72 IU) with instructed mimicry
Trial: 37137551
Drug: Exercise with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise with painful injection (hypertonic saline, 5.8%)
Trial: 37137551
Drug: Exercise with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise with non-painful injection (isotonic saline, 0.9%)
Trial: 37137551
Drug: Painful injection
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Painful injection (hypertonic saline, 5.8%)
Trial: 37137551
Drug: Non-painful injection
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-painful injection (isotonic saline, 0.9%)
Trial: 34417343
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous lidocaine infusion
Trial: 34417343
Drug: Ultrasound-guided unilateral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided unilateral, single-injection TAP block
Trial: 34648905
Drug: Coffee beverage
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coffee beverage A (400 mL/day containing 787 mg of chlorogenic acids)
Trial: 34648905
Drug: Coffee beverage
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coffee beverage B (400 mL/day containing 407 mg of chlorogenic acids)
Trial: 32619388
Drug: Non-biologics
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-biologics
Trial: 33712253
Drug: 1 µg.kg-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 µg.kg-1 clonidine intravenously
Trial: 34272849
Drug: lonapegsomatropin 0.24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lonapegsomatropin 0.24 mg hGH/kg/week
Trial: 34272849
Drug: daily somatropin
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily somatropin (equivalent weekly dose delivered daily)
Trial: 32561603
Drug: MSCT monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSCT monotherapy
Trial: 32561603
Drug: MSCT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSCT plus recombinant human IFN-γ treatment
Trial: 35242203
Drug: Dynamic monitoring
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic monitoring of lipid metabolism indexes and regulation of blood lipids on top of routine hypoglycemic treatment (Group B)
Trial: 35242203
Drug: Routine hypoglycemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine hypoglycemic treatment (Control Group)
Trial: 35242203
Drug: Combined detection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined detection of lipid metabolism indexes (TC, TG, HDL-C, LDL-C)
Trial: 32003816
Drug: Telemedicine intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telemedicine intervention (weekly for 4 weeks, every 2 weeks for 4 weeks, and monthly thereafter, provided relapse prevention therapy and buprenorphine)
Trial: 32003816
Drug: In-person intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In-person intervention (weekly for 4 weeks, every 2 weeks for 4 weeks, and monthly thereafter, provided relapse prevention therapy and buprenorphine)
Trial: 35912650
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (ET)
Trial: 32041720
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept (Eylea) given via loading dose (three injections) followed by treat and extend protocol over 12 months
Trial: 34014028
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg naltrexone
Trial: 34014028
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg amitriptyline
Trial: 34654525
Drug: Weekly participatory
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly participatory art-based activities at the Montreal Museum of Fine Arts over a 3-month period
Trial: 33450079
Drug: ONO-7684 (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONO-7684 (250 mg daily for 14 days)
Trial: 33450079
Drug: ONO-7684 (1-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONO-7684 (1-300 mg single doses)
Trial: 33450079
Drug: ONO-7684 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONO-7684 (single and multiple doses)
Trial: 33450079
Drug: ONO-7684 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONO-7684 (single doses)
Trial: 33450079
Drug: ONO-7684 (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONO-7684 (multiple doses)
Trial: 34846023
Drug: DBC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBC treatment with modern rehabilitation equipment
Trial: 36006997
Drug: Routine physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine physical therapy (RPT)
Trial: 33685871
Drug: App-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: App-based treatment (URinControl)
Trial: 32041657
Drug: MTX 25
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX 25 mg (oral or subcutaneous) once weekly plus LEF 20 mg daily
Trial: 32041657
Drug: Placebo instead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo instead of LEF daily
Trial: 32030734
Drug: Goal-directed fluid
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed fluid therapy (n = 142)
Trial: 32030734
Drug: Standard fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard fluid therapy (n = 141)